Subtherapeutic concentrations of infliximab and adalimumab are associated with increased disease activity in Crohn's disease.
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Tore Grimstad Lars Aabakken |
| Publication date | March 14, 2018 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |